Latest revenue
$93.5M
as of 2026-04-03
Latest net income
$5.2M
as of 2026-04-03
Net margin
5.6%
as of 2026-04-03
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.61B
- Enterprise value
- $1.61B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $35.87
- 52-wk low
- $15.59
- Beta
- —
- Shares out
- 49.5M
5-year trend
What this company does
ITEM 1. Business STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. Unless the context indicates otherwise, “we,” “us,” the “Company,” and…
AI summary unavailable — showing raw filing excerpt
Generated from STAA's filing dated 2026-03-03
Key risks
ITEM 1A. Risk Factors Investment in our securities involves a high degree of risk. Investors should carefully consider the following risk factors, in addition to other information contained in this Annual Report and other filings that we make from time to time with the SEC, before making a decision to invest in our common stock. Any of the following risks, as well as other risks that we cannot foresee at this time or that we currently view to be immaterial, could materially and adversely affect our business, financial condition, results of operations or cash flows. The trading price of our common stock could decline due to any of these risks, and investors may lose all or part of their…
AI summary unavailable — showing raw filing excerpt
Generated from STAA's filing dated 2026-03-03
Profitability
Gross margin
76.2%
0.2%Operating margin
-38.3%
853.4%Net margin
-33.6%
421.9%Return on equity
-23.4%
346.4%Return on assets
-17.8%
349.1%Leverage
Debt / equity
0.31×
2.5%Long-term debt / equity
0.00×
86.6%Debt / assets
23.8%
1.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q2 2026 2026-04-03 | $93.5M | +119.6% | $5.2M | +109.6% | 5.6% |
Q1 2026 2026-01-02 | $57.8M | +18.1% | $-18.3M | +40.7% | -31.7% |
Q3 2025 2025-09-26 | $94.7M | +6.9% | $8.9M | -11.0% | 9.4% |
Q2 2025 2025-06-27 | $44.3M | -55.2% | $-16.8M | -516.1% | -37.9% |
Q1 2025 2025-03-28 | $42.6M | -44.9% | $-54.2M | -1523.6% | -127.3% |
Q4 2024 2024-12-27 | $49.0M | — | $-30.9M | — | -63.1% |
Q3 2024 2024-09-27 | $88.6M | +10.3% | $10.0M | +107.2% | 11.3% |
Q2 2024 2024-06-28 | $99.0M | +7.3% | $4.0M | -33.4% | 4.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Ophthalmic Goods · SIC 3851
Your notes
Keep private notes on STAA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$62.8M
Insider selling
$0
Net activity
+$62.8M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns STAA
Institutional value
$360.3M
Total shares held
19.4M
Distinct holders
103
-96 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.7M | $124.7M | -694.2K (-9.4%) | Trimmed |
| 2 | Yunqi Capital Ltd | 3.3M | $60.9M | +750.0K (+29.9%) | Added |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.1M | $39.7M | — | New |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $31.6M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 820.8K | $15.3M | +230.6K (+39.1%) | Added |
| 6 | Defender Capital, LLC. | 644.5K | $12.1M | -23.7K (-3.5%) | Trimmed |
| 7 | JANE STREET GROUP, LLC | 442.2K | $8.3M | +113.4K (+34.5%) | Added |
| 8 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 359.7K | $6.7M | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 322.1K | $6.0M | — | New |
| 10 | BRIGHT VALLEY CAPITAL Ltd | 272.0K | $5.1M | — | New |
| 11 | AI-Squared Management Ltd | 268.1K | $5.0M | — | New |
| 12 | PRINCIPAL FINANCIAL GROUP INC | 242.0K | $4.5M | -21.3K (-8.1%) | Trimmed |
| 13 | Bank of New York Mellon Corp | 231.5K | $4.3M | -39.7K (-14.6%) | Trimmed |
| 14 | UBS Group AG | 179.9K | $3.4M | -147.9K (-45.1%) | Trimmed |
| 15 | Public Sector Pension Investment Board | 177.9K | $3.3M | +5.8K (+3.4%) | Added |
| 16 | Invesco Ltd. | 149.0K | $2.8M | -12.5K (-7.8%) | Trimmed |
| 17 | Nuveen, LLC | 137.9K | $2.6M | -23.1K (-14.3%) | Trimmed |
| 18 | RHUMBLINE ADVISERS | 129.3K | $2.4M | -9.4K (-6.8%) | Trimmed |
| 19 | Legal & General Group Plc | 101.7K | $1.9M | -12.3K (-10.8%) | Trimmed |
| 20 | CRCM LP | 100.0K | $1.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once STAA's latest filing finishes processing.